Review
New antimicrobial agents for methicillin-resistant Staphylococcus aureus
Affiliations
- PMID:20001879
Item in Clipboard
Review
New antimicrobial agents for methicillin-resistant Staphylococcus aureus
Marin H Kollef. Crit Care Resusc.2009 Dec.
Display options
Format
Display options
Format
Abstract
In bacterial and fungal infections, optimal outcomes are obtained through the timely provision of adequate antimicrobial coverage in an initial anti-infective treatment regimen. However, selecting appropriate antimicrobial regimens to treat infections in the intensive care unit is challenging because of the expansion of antibiotic resistance. Multidrug anti-infective regimens are typically needed to adequately cover common important pathogens in ICUs. Here, we describe novel antibacterial agents in the late stages of clinical development that show potential for treating methicillin-resistant Staphylococcus aureus (MRSA) infections. These include the fifth-generation cephalosporins, ceftaroline and ceftobiprole; the glycopeptides, dalbavancin, oritavancin, and telavancin; and iclaprim.
Comment in
- Gram versus gram.Stachowski E.Stachowski E.Crit Care Resusc. 2010 Mar;12(1):69; author reply 69.Crit Care Resusc. 2010.PMID:20196719No abstract available.
Similar articles
- New antibiotics for healthcare-associated pneumonia.Neuner EA, Ritchie DJ, Micek ST.Neuner EA, et al.Semin Respir Crit Care Med. 2009 Feb;30(1):92-101. doi: 10.1055/s-0028-1119813. Epub 2009 Feb 6.Semin Respir Crit Care Med. 2009.PMID:19199191Review.
- Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.Loffler CA, Macdougall C.Loffler CA, et al.Expert Rev Anti Infect Ther. 2007 Dec;5(6):961-81. doi: 10.1586/14787210.5.6.961.Expert Rev Anti Infect Ther. 2007.PMID:18039081
- A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Guskey MT, Tsuji BT.Guskey MT, et al.Pharmacotherapy. 2010 Jan;30(1):80-94. doi: 10.1592/phco.30.1.80.Pharmacotherapy. 2010.PMID:20030476Review.
- New treatments for methicillin-resistant Staphylococcus aureus.Stryjewski ME, Corey GR.Stryjewski ME, et al.Curr Opin Crit Care. 2009 Oct;15(5):403-12. doi: 10.1097/MCC.0b013e32832f0a74.Curr Opin Crit Care. 2009.PMID:19561492Review.
- Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria.Eliopoulos GM.Eliopoulos GM.J Infect. 2009 Sep;59 Suppl 1:S17-24. doi: 10.1016/S0163-4453(09)60004-9.J Infect. 2009.PMID:19766885Review.
Cited by
- A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline.Kiang TK, Wilby KJ, Ensom MH.Kiang TK, et al.Clin Pharmacokinet. 2015 Sep;54(9):915-31. doi: 10.1007/s40262-015-0281-3.Clin Pharmacokinet. 2015.PMID:25940827Review.
- Acute bacterial skin and skin structure infections: current perspective.Shah M, Shah HD.Shah M, et al.Indian J Dermatol. 2011 Sep-Oct;56(5):510-2. doi: 10.4103/0019-5154.87134.Indian J Dermatol. 2011.PMID:22121265Free PMC article.
- Comparison of microplate and macrodilution methods in time-kill study of new antimicrobial drugs.Zhou Y, Hou Z, Fang C, Xue X, Da F, Wang Y, Bai H, Luo X.Zhou Y, et al.Folia Microbiol (Praha). 2013 Jan;58(1):9-16. doi: 10.1007/s12223-012-0168-8. Epub 2012 Jun 9.Folia Microbiol (Praha). 2013.PMID:22684972
- A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-ResistantStaphylococcus aureus (MRSA) Infections.Lounsbury N, Reeber MG, Mina G, Chbib C.Lounsbury N, et al.Antibiotics (Basel). 2019 Mar 20;8(1):30. doi: 10.3390/antibiotics8010030.Antibiotics (Basel). 2019.PMID:30897759Free PMC article.Review.
- Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury.Faris J, Mynatt RP, Hall Snyder AD, Rybak MJ.Faris J, et al.Infect Dis Ther. 2015 Dec;4(4):519-28. doi: 10.1007/s40121-015-0096-4. Epub 2015 Nov 5.Infect Dis Ther. 2015.PMID:26541469Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Medical